Browsing Tag

ORGOVYX

Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement…

Eli Pacheco May 9, 2022 0

Myovant to receive an upfront payment of $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to $90.5 millionMyovant also eligible to receive…

Health

Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for…

Eli Pacheco Apr 30, 2022 0

ORGOVYX® is the first and only oral androgen deprivation therapy for advanced hormone-sensitive prostate cancer in EuropeMyovant expects to secure European commercialization partner ahead…

Health

Myovant Sciences Receives Positive CHMP Opinion for ORGOVYX® (relugolix) for the…

Eli Pacheco Feb 25, 2022 0

CHMP opinion recommending approval based on data from the global Phase 3 HERO study If approved, ORGOVYX® would be the first and only oral androgen deprivation therapy for advanced…